Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody–Drug Conjugates
Yutaka Matsuda(Ajinomoto (United States)), Tatsuya Okuzumi(Suzuki (Japan)), Brian A. Mendelsohn(Seagen (United States)), Takahiro Narita(Suzuki (Japan)), Takuya Seki(Suzuki (Japan)), Kazutoshi Takahashi(Suzuki (Japan)), Yuri Ooba(Suzuki (Japan)), Kei Yamada(Kurume University), Tomohiro Fujii(Suzuki (Japan)), Akira Nakayama(Suzuki (Japan)), Yoshiro Kitahara(Nihon University), Sayaka Kawaguchi(Suzuki (Japan))
Cited by 61
Related Papers
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity
|Bioconjugate Chemistry|2005|511
Inhibitor hijacking of Akt activation
|Nature Chemical Biology|2009|296
Repetitive Fluctuations in Blood Glucose Enhance Monocyte Adhesion to the Endothelium of Rat Thoracic Aorta
|Arteriosclerosis Thrombosis and Vascular Biology|2006|163